Supplementary Figure 1 from Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of &lt;i&gt;HRAS&lt;/i&gt;, &lt;i&gt;TP53&lt;/i&gt;, and &lt;i&gt;TGFBR1&lt;/i&gt;